for people ages 18-110 (full criteria)
at Sacramento, California and other locations
study started
estimated completion



This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.

Official Title

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors


Solid Tumor, Adult Gastric (gastroesophageal cancer) Advanced Solid Tumor Colorectal cancer Cancer Metastatic Solid Tumor Combination Therapy CD39 Adenosine Pathway Immunotherapy Immuno-oncology PD-1 Checkpoint Inhibitor Docetaxel Budigalimab ABBV-181 TTX-030 Non-small cell lung cancer Urothelial cell cancer Pancreatic cancer Pembrolizumab Keytruda Bladder cancer Gemcitabine Nab-paclitaxel Neoplasms Paclitaxel Albumin-Bound Paclitaxel TTX-030, budigalimab and mFOLFOX6 TTX-030, budigalimab and docetaxel TTX-030 and mFOLFOX6 TTX-030 and budigalimab TTX-030, budigalimab, nab-paclitaxel and gemcitabine TTX-030 and pembrolizumab TTX-030, nab-paclitaxel and gemcitabine Budigalimab and mFOLFOX6 Combo 1 Combo 2 Combo 3 Combo 4 Combo 5 Combo 6 Combo 7 Combo 8


For people ages 18-110

Abbreviated Inclusion Criteria:

  1. Age 18 years or older, is willing and able to provide informed consent
  2. Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
  3. Life expectancy > 12 weeks
  4. ECOG performance status of 0-1

Abbreviated Exclusion Criteria:

  1. History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
  2. Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
  3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
  4. History of severe autoimmune disease
  5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment


  • UC Davis Comprehensive Cancer Center accepting new patients
    Sacramento California 95817 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States
  • UCLA Hematology/Oncology accepting new patients
    Los Angeles California 90404 United States


accepting new patients
Start Date
Completion Date
Trishula Therapeutics, Inc.
Sign up for this study
Phase 1
Study Type
Last Updated